Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Intervention not reported
Cramp intensity (moderate or worse at 4 weeks) · pregnant women with leg cramps
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Cramp intensity (moderate or worse at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp intensity (moderate or worse at 4 weeks) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
It is very uncertain whether regimens containing macrolides (azithromycin) changes clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (very low certainty).
2 findings from 1 review
RR 1.18 [0.89, 1.55]
Studies not reported
Very low
RR 1.35 [1.1, 1.67]
Studies not reported
Moderate
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
Regimens containing nitroimidazole showed no clear difference in clinical cure according to criteria established by study authors… compared with no nitroimidazole (moderate certainty).
2 findings from 1 review
RR 1.02 [0.95, 1.09]
Studies not reported
Moderate
RR 1.05 [1, 1.12]
Studies not reported
High
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
It is very uncertain whether regimens containing clindamycin plus aminoglycoside changes clinical cure according to criteria established by authors… compared with regimens containing quinolone (very low certainty).
1 finding from 1 review
RR 0.88 [0.69, 1.13]
Studies not reported
Very low
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
Regimens containing clindamycin plus aminoglycoside showed no clear difference in clinical cure according to criteria established by authors… compared with regimens containing cephalosporin (low certainty).
1 finding from 1 review
RR 1.02 [0.95, 1.09]
Studies not reported
Low
Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID
Regimens containing quinolone showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing cephalosporins (low certainty).
1 finding from 1 review
RR 1.05 [0.98, 1.14]
Studies not reported
Low
Participants' global self‐assessment of acne improvement Moderate to excellent improvement (long term: treatment duration > 8 weeks) · participants with acne
Salicylic acid showed no clear difference in participants' global self‐assessment of acne improvement Moderate to… compared with tretinoin (low certainty).
1 finding from 1 review
Intervention not reported
Time in moderate‐intensity physical activity · people with COPD, clinical stability
1 finding from 1 review
Time in moderate‐intensity physical activity · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Time in moderate‐intensity physical activity · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Change in time in moderate intensity physical activity · people with COPD, clinical stability
1 finding from 1 review
Disability or dependence in daily activities Patients with moderate or lower degree of disability or dependence (according to < 3 scores in the modified Rankin scale) lower scores indicate better outcome · people with acute ischemic stroke
Citicoline showed no clear difference in disability or dependence in daily activities Patients with moderate… compared with placebo or standard treatment (low certainty).
1 finding from 1 review
Neurodevelopmental outcomes (moderate/severe cognitive delay at 18 to 24 months) · preterm infants
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe cognitive delay at 18… compared with expectant management (low certainty).
1 finding from 1 review
Neurodevelopmental outcomes (moderate/severe motor delay at 18 to 24 months) · preterm infants
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe motor delay at 18 to 24… compared with expectant management (low certainty).
1 finding from 1 review
Neurodevelopmental outcomes (moderate/severe language delay at 18 to 24 months) · preterm infants
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe language delay at 18 to… compared with expectant management (low certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review